The government has launched a new campaign over social media and radio today (January 10) to encourage pregnant women to take their first, second and third dose of Covid-19 vaccine.
Joined by experts at the Royal College of Obstetricians and Gynaecologists (RCOG) and the Royal College of Midwives (RCM), the campaign highlights the risks of the infection and benefits of vaccination.
According to the latest data from the UK Health Security Agency (UKHSA), Covid-19 vaccinations are safe for pregnant women.
Department of Health and Social Care (DHSC) chief scientific adviser professor Lucy Chappell, said: "We have extensive evidence now to show that the vaccines are safe and that the risks posed by Covid-19 are far greater," calling upon pregnant women who have yet to have their jabs.
The campaign will also run testimonies of pregnant women who have had their jabs.
British health officials on Wednesday (September 28) warned that increased circulation of flu and a resurgence in Covid-19 could lead to a difficult winter that
increases pressure on the already stretched NHS.
Warnings over a possible "twindemic" of Covid-19 and flu have been issued each winter since the start of the coronavirus pandemic in early 2020, but Covid
restrictions that limited social contact have meant flu levels stayed low.
However, the government ended coronavirus restrictions earlier this year, meaning that social contact rates have returned to near pre-pandemic norms while immunity
to flu is relatively low.
The UK Health Security Agency (UKHSA) said that given the risk it was important those eligible took up vaccines against Covid and flu.
"There are strong indications we could be facing the threat of widely circulating flu, lower levels of natural immunity due to less exposure over the last three
winters and an increase in Covid-19 circulating," said Susan Hopkins, chief medical advisor at UKHSA.
The community pharmacy staff in Scotland will not be required to work for a minimum of five full days if they test positive for Covid-19.
The Scottish health secretary Humza Yousaf has clarified that health and social care employees, including community pharmacists, will have to follow the guidance
on managing staff with symptoms of a respiratory infection, or a positive Covid-19 test.
While responding to Jackie Baillie (Dumbarton) (Scottish Labour Party) written parliamentary question, Humza said, "If they work with patients or service users in
face-to-face settings, they can return to work if they have had two consecutive negative LFD test results (taken at least 24 hours apart)."
Jackie asked the Scottish government, "what its position is on the actions of Well Pharmacy, in light of reports that the company is insisting that staff who test
positive for COVID-19 continue to work when they are in patient-facing roles and dealing with clinically vulnerable people?"
The Pharmacists' Defence Association said: "This means that Well pharmacy will have to change their policy in Scotland and no longer allow Covid positive staff to
work in their pharmacies."
The NHS on Sunday (January 30) expanded its Covid-19 vaccination programme to include vulnerable children aged five to 11 years.
Eligible children include those with diabetes, immunosuppression, learning disabilities, and other conditions as outlined by the UK Health Security Agency in the Green Book.
Additionally, children living with someone immunosuppressed will be eligible to get the first dose of the Covid-19 vaccine in line with advice issued by the Joint Committee on Vaccination and Immunisation (JCVI).
According to the NHS, there are around 500,000 eligible children in the latest cohort.
GP and deputy lead for NHS vaccination programme Dr Nikki Kanani, said: "We know vaccines give significant protection against severe illness from Covid - including the omicron variant, so it is important that our youngest and most at-risk get protected.
Researchers from the University of Oxford today (December 8) started recruiting for a clinical trial to test novel antiviral Covid-19 treatments for early use in the illness by people in the community and those who are at higher risk of complications.
Partnering with the National Institute for Health Research (NIHR), colleagues in several UK universities, and the NHS UK-wide, the Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC), is a national priority trial, and will be open to participants from across the UK.
The first treatment to be tested by the UK Antiviral Taskforce will be molnupiravir, a Covid antiviral pill already licensed by the MHRA.
Britain became the first country in the world to approve molnupiravir, which was jointly developed by U.S.-based Merck & Co Inc and Ridgeback Biotherapeutics, in November.
The world has never been in a better position to end the Covid-19 pandemic, the head of the World Health Organization said on September 14, his most optimistic
outlook yet on the years-long health crisis which has killed over six million people.
"We are not there yet. But the end is in sight," WHO Director-General Tedros Adhanom Ghebreyesus told reporters at a virtual press conference.
That was the most upbeat assessment from the UN agency since it declared an international emergency in January 2020 and started describing Covid-19 as a pandemic
three months later.
The virus, which emerged in China in late 2019, has killed nearly 6.5 million people and infected 606 million, roiling global economies and overwhelming healthcare
systems.
The rollout of vaccines and therapies have helped to stem deaths and hospitalisations, and the Omicron variant which emerged late last year causes less severe
disease. Deaths from Covid-19 last week were the lowest since March 2020, the U.N. agency reported.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a second "bivalent" vaccine as a Covid-19 booster.
The updated booster vaccine made by Pfizer/BioNTech, targeting two coronavirus variants, has been approved for use in individuals aged 12 years and above.
In each dose of the booster vaccine, 'Comirnaty bivalent Original/Omicron', half of the vaccine (15 micrograms) targets the original virus strain and the other
half (15 micrograms) targets Omicron (BA.1).
Dr June Raine, MHRA chief executive said: "I am pleased to announce that we now have a second approved vaccine for the UK Autumn booster programme. The clinical
trial of the Pfizer/BioNTech bivalent vaccine showed a strong immune response against the Omicron BA.1 variant as well as the original strain.
Bivalent vaccines are helping us to meet the challenge of an ever-evolving virus, to help protect people against Covid-19 variants. We have in place a comprehensive
safety surveillance strategy for all UK-approved Covid-19 vaccines, and this will include the updated booster we approved today."
The National Institute for Health and Care Excellence (NICE) has issued draft guidance on 'Evusheld' which is not recommended for vulnerable adult with high
risk of severe Covid-19 on Thursday (16 February).
The draft guidance is open for public consultation until 9 March 2023. The committee will consider any comments received at a meeting currently due to take place on
4 April 2023.
It comes after last month's decision by the US drug regulator to withdraw its emergency use authorisation for Evusheld as a preventative treatment for Covid-19,
which said there was insufficient evidence that Evusheld is effective against the dominant variants of Covid-19 in the US.
NICE's independent appraisal committee has reached the same conclusion having considered evidence which shows Evusheld is unlikely to prevent infection with most of
the variants circulating in the UK now and in the near future.
It has also announced that it is developing a new review process to update recommendations on the cost-effectiveness of Covid-19 treatments so they can be made
available more quickly to patients if they show promise against new variants and are found to be cost-effective.
The government has accepted the Joint Committee on Vaccination and Immunisation's (JCVI) advice for the autumn 2024 COVID-19 vaccination programme.
According to the JCVI, the following groups will be eligible for vaccination this autumn:
Individuals aged 65 and over
Residents of care homes for older adults
Those aged 6 months and older in clinical risk groups
Minister for Public Health and Prevention, Andrew Gwynne, emphasised the importance of protecting vulnerable populations from COVID-19 and reducing pressure on
the NHS.
He said: "We are committed to protecting those most vulnerable from COVID and have accepted the independent advice from the JCVI for the autumn 2024 vaccination
programme."
"I encourage anyone invited for a vaccine to get one as soon as possible to protect yourself and reduce pressure on the NHS during winter, helping to cut waiting
times and get the health service back on its feet."
The Department of Health and Social Care (DHSC) announced that free COVID-19 lateral flow tests will be supplied through community pharmacies for at-risk groups.
The service will operate from 6 November for patients aged over 12 years who are at risk of developing severe COVID-19 symptoms.
Community pharmacies that have participated in this new initiative will be paid £4 plus VAT for each box of five lateral flow device test kits provided.
Alastair Buxton, Director of NHS services at Community Pharmacy England said: "This is not going to be a high-volume service, but community pharmacy teams
are well placed to provide LFD test kits to eligible patients with them having made over 25.5 million supplies of COVID-19 LFD test kits in 2021/22.
Representatives from the National Pharmacy Association (NPA) and the Royal Pharmaceutical Society (RPS) presented their preliminary evidence to the Inquiry,
which is examining the impact of the COVID-19 pandemic on healthcare systems in the UK.
The UK COVID-19 Inquiry began on 28 June 2022 to examine the UK's preparedness and response to the pandemic, aiming to draw insights for the future. Its
investigations are organised into modules, gathering evidence from witnesses, experts and core participants through a series of corresponding hearings throughout
each module.
A preliminary Module 3 hearing for its investigation into was held at Dorland House, 121 Westbourne Terrace, London, W2 6BU on Wednesday 10 April at 10.30am.
NPA calls for funding to boost pharmacy resilience
Presenting its evidence before the inquiry, the NPA highlighted the unsung contribution of pharmacies nationwide in combatting COVID-19 and maintaining health
services throughout the pandemic while calling for funding to create greater resilience in community pharmacies.
The National Pharmacy Association (NPA) and Royal Pharmaceutical Society (RPS) has been appointed as a core participant in the Covid-19 public inquiry.
The independent public inquiry has been set up to examine the UK's response to and the impact of the Covid-19 pandemic and learn lessons to shape preparations for
future pandemics. It is chaired by Baroness Heather Hallett, a former Court of Appeal judge.
The NPA and RPS will be part of Module 3, which covers the impact of Covid-19 on healthcare systems across the United Kingdom. The preliminary hearing for that
module takes place on Tuesday 28 February.
This will give the association an opportunity to make opening and closing statements, consider evidence provided to the Inquiry and propose questions to be asked by
the Inquiry of witnesses.
NPA chief executive, Mark Lyonette, said: "This is an historic opportunity to place on record the achievements of community pharmacy during the pandemic and to ensure
that the inquiry's recommendations are based in the practical realities faced by health workers such as our members.
Community pharmacies played a central role in the government's response to the Covid-19 pandemic, delivering more than 22 million jabs in the past 12 months.
Besides delivering millions of jabs, latest figures from NHS England and NHS Improvement (NHSE&I) revealed a 50 per cent increase in the number of pharmacies
delivering Covid boosters compared from October 2021 to January 2022.
NHSE&I released the data on Friday (January 14) to thank community pharmacy teams for their work during the crisis time.
Lauding the efforts made by community pharmacy teams during the pandemic, Pharmaceutical Services Negotiating Committee (PSNC) director of NHS Services Alastair Buxton said: "Just over a year ago we were fighting for Government recognition of the part community pharmacy could play in administering Covid vaccines, so a year later it is great to see the efforts of the pharmacy vaccination sites being praised by NHSE&I, with recognition of the significant role they have played in the overall programme.
Health secretary Sajid Javid visited Medicine Chest Pharmacy in London on Friday (January 28) and thanked pharmacy teams across England for delivering well over 20 million Covid-19 jabs.
According to the latest research conducted by the National Pharmacy Association (NPA) and PharmData, independent community pharmacies were the biggest deliverers of Covid-19 vaccines during January 2021 to September 2021 as compared to corporate-run pharmacy sites.
As of January 2022, pharmacies across the whole sector had delivered 22 million Covid jabs, with the majority of them being independents of whom most are NPA members.
In a video message released after the visit, Javid said: "Today I am here at Medicine Chest pharmacy in London to thank them, all pharmacies, the NHS, for the fantastic job they have done particularly over the last few months to get our country boosted. It's because of this phenomenal success that today we are able to return to Plan A as we see Omicron in retreat and we learn to live with Covid."
The General Pharmaceutical Council reiterated its stand on Covid-19 vaccination, saying, "Pharmacists and pharmacy technicians working in all settings across Great Britain should be vaccinated against Covid -19, unless they are medically exempt."
In a statement issued today (February 11), it strongly urged all pharmacyprofessionals, students and trainees to get fully vaccinated at the earliest.
This reiteration follows the government's announcement on January 31, 2022 that it would not proceed with Covid vaccination as a mandatory condition of deployment
for health and care staff providing CQC-regulated services in England.
The Council stated that clinical trials have proven the efficacy and safety of Covid vaccines and the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised their use in the UK.
Britain will start to roll out Merck's molnupiravir Covid-19 antiviral pill through a drug trial later this month, Susan Hopkins, chief medical adviser at the UK Health Security Agency said on Sunday (November 7).
Last week Britain became the first country in the world to approve the potentially game-changing Covid-19 antiviral pill, jointly developed by US-based Merck & Co Inc and Ridgeback Biotherapeutics.
The government said in October it had secured 480,000 courses of the Merck drug, as well as 250,000 courses of an antiviral pill developed by Pfizer Inc.
Asked about the molnupiravir approval, Hopkins told BBC television: "That is great news and it will start to be rolled out through a drug trial in the end of this month/the beginning of December."
Hopkins said all the trials so far had been done with the unvaccinated, so this would help understand how it will work in the wider vaccinated population.
Britain has approved Novavax's Covid-19 vaccine for use in those 18 years of age and older, the country's medicines regulator said on Thursday (February 3), bringing a fifth coronavirus shot to its roster amidst the rapid spread of the Omicron variant.
The vaccine, Nuvaxovid, was approved as a first and second dose as it met the required safety, quality and effectiveness standards, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement.
The British approval for Nuvaxovid comes days after the drugmaker filed for US authorisation of the vaccine following months of struggles with development and manufacturing problems, and follows a German backing earlier in the day.
"We are continuing our vital safety work in monitoring the use of all Covid-19 vaccines, to ensure that their benefits in protecting people against Covid-19 disease continue to outweigh any risks," MHRA chief executive June Raine said.
The NHS on Sunday (January 30) expanded its Covid-19 vaccination programme to include vulnerable children aged five to 11 years.
Eligible children include those with diabetes, immunosuppression, learning disabilities, and other conditions as outlined by the UK Health Security Agency in the Green Book.
Besides, children living with someone immunosuppressed will be eligible to get the first dose of the Covid vaccine in line with advice issued by the Joint Committee on Vaccination and Immunisation (JCVI).
According to the NHS there are around 500,000 eligible children in the latest cohort.
GP and deputy lead for NHS vaccination programme Dr Nikki Kanani, said: "We know vaccines give significant protection against severe illness from Covid - including the omicron variant, so it is important that our youngest and most at-risk get protected.
Researchers have projected the rates of liver disease and associated deaths due to increased alcohol consumption during the Covid-19 pandemic.
The research has been published in the 'Hepatology Journal'.
A team led by investigators at Massachusetts General Hospital used data from a national survey of US adults on their drinking habits that found that excessive drinking (such as binge drinking) increased by 21 per cent during the Covid-19 pandemic.
The scientists simulated the drinking trajectories and liver disease trends in all US adults.
They estimated that a one-year increase in alcohol consumption during the Covid-19 pandemic will result in 8,000 additional deaths from alcohol-related liver disease, 18,700 cases of liver failure, and 1,000 cases of liver cancer by 2040. In the short term, alcohol consumption changes due to Covid-19 are expected to cause 100 additional deaths and 2,800 additional cases of liver failure by 2023.
The researchers noted that a sustained increase in alcohol consumption for more than one year could result in 19-35 per cent additional mortality.
It is not sustainable to give Covid-19 booster shots every three to six in the long term, Britain's chief scientific adviser said on Tuesday (January 4), even though the booster rollout is needed in the short term to combat the Omicron variant.
"It would be a situation that isn't tenable to say everyone's going to need to be having another vaccine every three or six months.
"That's not the long-term view of where this goes to," Patrick Vallance said at a news conference, adding that annual booster shots against Covid-19 might be necessary, similar to flu shots.